Although natalizumab (NTZ) is most frequently involved, PML also occurs less commonly with sphingosine-1-phosphate receptor modulators (S1P-RM), dimethyl fumarate (DMF), and ocrelizumab. The gene discussed is S1PR1; the disease is progressive multifocal leukoencephalopathy.